Fig. 1 | Bone Marrow Transplantation

Fig. 1

From: Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma

Fig. 1

Clinical parameters and cytokine levels with axi-cel and post progression nivolumab treatment. a Serum LDH (right axis), ALC, and CAR T-cell levels (left axis) are shown starting at day −8, during lymphodepleting chemotherapy (Flu/Cy, days −6, −4, and −3), through axi-cel infusion (day 0) and dosing of nivolumab (days 11, 23, and 35). b CAR T-cell levels for the case study patient and the median for all other patients in ZUMA-1 are shown over the course of treatment. c Serum cytokine levels before and during treatment. ALC absolute lymphocyte count, axi-cel axicabtagene ciloleucel, CAR chimeric antigen receptor, CRP C-reactive protein, Flu/Cy fludarabine and cyclophosphamide, IFNγ interferon-γ, IL-15 interleukin-15, LDH lactate dehydrogenase, PD-L1 programmed death-ligand 1

Back to article page